Attached files

file filename
EX-31.2 - CERTIFICATION - PANAMERA HEALTHCARE Corppnht_ex312.htm
EX-32.2 - CERTIFICATION - PANAMERA HEALTHCARE Corppnht_ex322.htm
EX-32.1 - CERTIFICATION - PANAMERA HEALTHCARE Corppnht_ex321.htm
EX-31.1 - CERTIFICATION - PANAMERA HEALTHCARE Corppnht_ex311.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

 

x

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended January 31, 2018

 

or

 

¨

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______________ to ______________

 

Commission File Number 000-55569

 

PANAMERA HEALTHCARE CORPORATION

(Exact name of registrant as specified in its charter)

 

Nevada

 

46-5707326

(State or other jurisdiction of incorporation or organization)

 

(IRS Employer Identification No.)

 

4180 Orchard Hill Drive, Edmond, OK

 

73025

(Address of principal executive offices)

 

(Zip Code)

 

(405) 413-5735

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x YES    o NO

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x YES    o NO

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

¨

Accelerated filer

¨

Non-accelerated filer

¨

(Do not check if a smaller reporting company)

Smaller reporting company

x

 

Emerging growth company

x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) x YES    o NO

 

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS

 

Check whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court. o YES    o NO

 

APPLICABLE ONLY TO CORPORATE ISSUERS

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

17,990,000 common shares issued and outstanding as of March 15, 2018.

 

 
 
 
 

TABLE OF CONTENTS

 

PART I - FINANCIAL INFORMATION

 

 

 

Item 1.

Financial Statements

 

3

 

Item 2.

Management’s Discussion and Analysis of Financial Condition or Plan of Operation

 

4

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

 

7

 

Item 4.

Controls and Procedures

 

7

 

PART II - OTHER INFORMATION

 

8

 

Item 1.

Legal Proceedings

 

9

 

Item 1A.

Risk Factors

 

9

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

 

9

 

Item 3.

Defaults Upon Senior Securities

 

9

 

Item 4.

Mine Safety Disclosures

 

9

 

Item 5.

Other Information

 

9

 

Item 6.

Exhibits

 

10

 

SIGNATURES

 

11

 

 
2
 
Table of Contents

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

PANAMERA HEALTHCARE CORPORATION

 

Index to the Unaudited Interim Financial Statements

 

January 31, 2018

 

Page

 

Balance sheets as of January 31, 2018 (unaudited) and July 31, 2017

F-1

 

 

Statements of operations for the three and six months ended January 31, 2018 and 2017 (unaudited)

F-2

 

 

Statements of cash flows for the six months ended January 31, 2018 and 2017 (unaudited)

F-3

 

 

Notes to the unaudited interim financial statements

F-4

 

 

 
3
 
Table of Contents

 

PANAMERA HEALTHCARE CORPORATION

Balance Sheets

(Unaudited)

 

 

 

January 31,

 

 

July 31,

 

 

 

2018

 

 

2017

 

ASSETS

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

Cash and cash equivalents

 

$ 2,173

 

 

$ 13,460

 

Total Current Assets

 

 

2,173

 

 

 

13,460

 

 

 

 

 

 

 

 

 

 

TOTAL ASSETS

 

$ 2,173

 

 

$ 13,460

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' DEFICIT

 

 

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

$ 10,615

 

 

$ 3,568

 

Accrued interest - related party

 

 

1,616

 

 

 

642

 

Due to related party

 

 

38,601

 

 

 

38,601

 

Total Current Liabilities

 

 

50,832

 

 

 

42,811

 

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES

 

 

50,832

 

 

 

42,811

 

 

 

 

 

 

 

 

 

 

Stockholders' Deficit

 

 

 

 

 

 

 

 

Preferred stock: 50,000,000 authorized; $0.0001 par value

 

 

 

 

 

 

 

 

no shares issued and outstanding

 

 

-

 

 

 

-

 

Common stock: 150,000,000 authorized; $0.0001 par value

 

 

 

 

 

 

 

 

17,990,000 shares issued and outstanding

 

 

1,799

 

 

 

1,799

 

Additional paid in capital

 

 

145,750

 

 

 

145,750

 

Accumulated deficit

 

 

(196,208 )

 

 

(176,900 )

Total Stockholders' Deficit

 

 

(48,659 )

 

 

(29,351 )

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT

 

$ 2,173

 

 

$ 13,460

 

 

The accompanying notes to the unaudited interim financial statements are an integral part of these statements.

 

 
F-1
 
Table of Contents

 

PANAMERA HEALTHCARE CORPORATION

Statements of Operations

(Unaudited)

 

 

 

For the

 

 

For the

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

January 31,

 

 

January 31,

 

 

 

2018

 

 

2017

 

 

2018

 

 

2017

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Expenses

 

 

 

 

 

 

 

 

 

 

 

 

Professional expenses

 

$ 5,678

 

 

$ 6,381

 

 

$ 17,615

 

 

$ 14,326

 

General and administration expenses

 

 

348

 

 

 

383

 

 

 

720

 

 

 

679

 

Total operating expenses

 

 

6,026

 

 

 

6,764

 

 

 

18,335

 

 

 

15,005

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss from operations

 

 

(6,026 )

 

 

(6,764 )

 

 

(18,335 )

 

 

(15,005 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

(487 )

 

 

(663 )

 

 

(973 )

 

 

(1,355 )

Total other expense

 

 

(487 )

 

 

(663 )

 

 

(973 )

 

 

(1,355 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss before taxes

 

 

(6,513 )

 

 

(7,427 )

 

 

(19,308 )

 

 

(16,360 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax benefit

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$ (6,513 )

 

$ (7,427 )

 

$ (19,308 )

 

$ (16,360 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted net loss per common share

 

$ (0.00 )

 

$ (0.00 )

 

$ (0.00 )

 

$ (0.00 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding, basic and diluted

 

 

17,990,000

 

 

 

17,990,000

 

 

 

17,990,000

 

 

 

17,990,000

 

 

The accompanying notes to the unaudited interim financial statements are an integral part of these statements.

 

 
F-2
 
Table of Contents

 

PANAMERA HEALTHCARE CORPORATION

Statements of Cash Flows

(Unaudited)

 

 

 

For the

 

 

 

Six Months Ended

 

 

 

January 31,

 

 

 

2018

 

 

2017

 

 

 

 

 

 

 

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net loss

 

$ (19,308 )

 

$ (16,360 )

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

 

7,047

 

 

 

5,066

 

Accrued interest - related party

 

 

974

 

 

 

(277 )

Net Cash Used In Operating Activities

 

 

(11,287 )

 

 

(11,571 )

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Repayments on related party loans

 

 

-

 

 

 

(3,483 )

Net Cash Used In Financing Activities

 

 

-

 

 

 

(3,483 )

 

 

 

 

 

 

 

 

 

Net decrease in cash and cash equivalents

 

 

(11,287 )

 

 

(15,054 )

Cash and cash equivalents, beginning of period

 

 

13,460

 

 

 

60,084

 

Cash and cash equivalents, end of period

 

$ 2,173

 

 

$ 45,030

 

 

 

 

 

 

 

 

 

 

Supplemental cash flow information

 

 

 

 

 

 

 

 

Cash paid for interest

 

$ -

 

 

$ 1,631

 

Cash paid for taxes

 

$ -

 

 

$ -

 

 

The accompanying notes to the unaudited interim financial statements are an integral part of these statements.

 

 
F-3
 
Table of Contents

 

PANAMERA HEALTHCARE CORPORATION

Notes to the Unaudited Interim Financial Statements

January 31, 2018

 

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Panamera Healthcare Corporation (the “Company”) is a Nevada corporation incorporated on May 20, 2014. It is based in Oklahoma City, OK, USA. The accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America, and the Company’s fiscal year end is July 31.

 

The Company intends to offer management and consulting services to healthcare organizations that are increasingly facing various stresses including financial, organizational, and information technology challenges. To date, the Company’s activities have been limited to its formation and the raising of equity capital.

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the unaudited interim financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

 

In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the unaudited interim financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year. The accompanying unaudited interim financial statements should be read in conjunction with the financial statements and related notes included in the Company’s Annual Report on Form 10-K, for the year ended July 31, 2017, as filed with the SEC on October 30, 2017.

 

NOTE 3 - GOING CONCERN

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. As of January 31, 2018, the Company has a loss from operations, an accumulated deficit and has not earned any revenues. The Company intends to fund operations through equity financing arrangements, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for the year ending July 31, 2018.

 

The ability of the Company to emerge from an early stage is dependent upon, among other things, obtaining additional financing to continue operations, and development of its business plan. In response to these problems, management intends to raise additional funds through public or private placement offerings.

 

These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

 
F-4
 
Table of Contents

 

NOTE 4 - RELATED PARTY TRANSACTIONS

 

Note Payable

 

On July 15, 2014, a corporation controlled by an officer and director committed $75,000 Promissory Note in the form of an unsecured line of credit. Any unpaid balance was due December 31, 2015, and was extended to December 31, 2018, at an annual interest rate of 5% and may be prepaid without penalty. The Company concluded the note modification was not a significant change and is not treating it as an extinguishment. During the six months ended January 31, 2018 and 2017, net repayments under the line of credit to the Company were made in the amount of $0 and $3,483, respectively. As of January 31, 2018, the Company was obligated, for this interest bearing loan with a balance of $38,601 and accrued interest of $1,616. As of July 31, 2017, the Company was obligated, for this interest-bearing loan with a balance of $38,601 and accrued interest of $642. The Company plans to pay the loan and interest back as cash flows become available. The remaining balance available under the line of credit is $34,783 as of January 31, 2018. For the periods ended January 31, 2018 and 2017, the Company paid $0 and $1,631, respectively, in interest on this note payable.

 

Other

 

The Company does not own or lease property or lease office space. The office space used by the Company was arranged by the founder of the Company to use at no charge.

 

 
F-5
 
Table of Contents

 

Item 2. Management’s Discussion and Analysis of Financial Condition or Plan of Operation

 

The following discussion should be read in conjunction with our financial statements, including the notes thereto, appearing elsewhere in this annual report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to those discussed below and elsewhere in this report. Our unaudited financial statements are stated in United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles.

 

Plan of Operations and Cash Requirements

 

We intend to devote our marketing efforts toward identifying ambulatory surgical centers (ASC) that currently have an incentive to be acquired by hospitals in order to increase compensation levels. We intend to reorganize ASCs and consolidate several such centers into larger entities that can immediately take advantage of higher reimbursement rates permitted by the reorganization. At the same time, we expect to institute the necessary medical records and management systems to make the transition to value based compensation.

 

Cash Requirements

 

We have incurred recurring losses to date. Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation. We expect we will require additional capital to meet our long term operating requirements. We expect to raise additional capital through equity financing arrangements.

 

Results of Operations for the three months ended January 31, 2018 and 2017

 

The following table provides selected financial data about our company as of the three months, ended January 31, 2018 and 2017.

 

 

 

For the Three Months Ended

 

 

 

 

 

 

January 31,

 

 

 

 

 

 

2018

 

 

2017

 

 

Changes ($)

 

Total operating expenses

 

$ 6,026

 

 

$ 6,764

 

 

$ (738 )

Other expenses

 

$ 487

 

 

$ 663

 

 

$ (176 )

Net loss

 

$ 6,513

 

 

$ 7,427

 

 

$ (914 )

 

During the three months ended January 31, 2018 and 2017, no revenues were recorded.

 

We had a net loss $6,513 for the three months ended January 31, 2018, and $7,427 for the same period ended January 31, 2017. The decrease in net loss of $914, was primarily due to the decrease in operating expenses.

 

Operating expenses for the three months ended January 31, 2018 and 2017 were $6,026 and $6,764, respectively. The operating expenses were primarily attributed to professional fees for maintaining reporting status with the Securities and Exchange Commission (“SEC”) and general and administrative expenses. Professional fees for the three months ended January 31, 2018, was $5,678 compared to $6,381 for the same period ended January 31, 2017. General and administration expenses decreased by $35, to $348 for the three months ended January 31, 2018, from $383 for the three months ended January 31, 2017.

 

Other expenses represent interest paid to a related party on funds advanced to the Company.

 

 
4
 
Table of Contents

 

Results of Operations for the six months ended January 31, 2018 and 2017

 

The following table provides selected financial data about our company as of the six months, ended January 31, 2018 and 2017.

 

 

 

For the Six Months Ended

 

 

 

 

 

January 31,

 

 

 

 

 

2018

 

 

2017

 

 

Changes ($)

 

Total operating expenses

 

$ 18,335

 

 

$ 15,005

 

 

$ 3,330

 

Other expenses

 

$ 973

 

 

$ 1,355

 

 

$ (382 )

Net loss

 

$ 19,308

 

 

$ 16,360

 

 

$ 2,948

 

 

During the six months ended January 31, 2018 and 2017, no revenues were recorded.

 

We had a net loss $19,308 for the six months ended January 31, 2018, and $16,360 for the same period ended January 31, 2017. The increase in net loss of $2,948, was primarily due to the increase in operating expenses.

 

Operating expenses for the six months ended January 31, 2018 and 2017 were $18,335 and $15,005, respectively. The operating expenses were primarily attributed to professional fees for maintaining reporting status with the Securities and Exchange Commission (“SEC”) and general and administrative expenses. Professional fees for the six months ended January 31, 2018, was $17,615 compared to $14,326 for the same period ended January 31, 2017. General and administration expenses increased by $41, to $720 for the six months ended January 31, 2018, from $679 for the six months ended January 31, 2017.

 

Other expenses represent interest paid to a related party on funds advanced to the Company.

 

Balance Sheet Data:

 

 

 

 

 

 

 

 

January 31,

2018

 

 

July 31,

2017

 

 

Changes ($)

 

Cash

 

$ 2,173

 

 

$ 13,460

 

 

$ (11,287 )

Working capital (deficiency)

 

$ (48,659 )

 

$ (29,351 )

 

$ (19,308 )

Total assets

 

$ 2,173

 

 

$ 13,460

 

 

$ (11,287 )

Total liabilities

 

$ 50,832

 

 

$ 42,811

 

 

$ 8,021

 

Total stockholders' equity (deficit)

 

$ (48,659 )

 

$ (29,351 )

 

$ (19,308 )

 

As of January 31, 2018, our current assets were $2,173 and our current liabilities were $50,832 which resulted in working capital deficiency of $48,659. As of January 31, 2018, our current assets were comprised of $2,173 in cash, compared to $13,460 in cash as of July 31, 2017. As of January 31, 2018, current liabilities were comprised of $10,615 in accounts payable and $40,217 in due to related party and accrued interest, compared to $3,568 in accounts payable and $39,243 in due to related party and accrued interest as of July 31, 2017.

 

As of January 31, 2018, our working capital decreased by $19,308 from a deficiency of $29,351 on July 31, 2017, to $48,659 on January 31, 2018, primarily due to decrease in cash of $11,287 and an increase in accounts payable of $7,047

 

Cash Flow Data:

 

 

 

 

 

 

 

 

 

 

For the Six Months Ended

 

 

 

 

 

January 31,

 

 

 

 

 

2018

 

 

2017

 

 

Changes ($)

 

Cash Flows used in Operating Activities

 

$ (11,287 )

 

$ (11,571 )

 

$ (284 )

Cash Flows used in Financing Activities

 

$ -

 

 

$ (3,483 )

 

$ 3,483

 

Net Decrease In Cash During Period

 

$ (11,287 )

 

$ (15,054 )

 

$ (3,767 )

 

 
5
 
Table of Contents

 

Cash Flows from Operating Activities

 

We have not generated positive cash flows from operating activities. For the six months ended January 31, 2018, net cash flows used in operating activities was $11,287, consisting of a net loss of $19,308, reduced by an increase in accounts payable and accrued liabilities of $7,047 and in accrued interest due to related parties of $947. For the period ended January 31, 2017, net cash flows used in operating activities was $11,571, consisting of a net loss of $16,360 and was offset by an increase in accounts payable and accrued liabilities of $5,066 and by a decrease in accrued expense of $277.

 

Cash Flows from Financing Activities

 

We have financed our operations from the issuance of equity and loans from related parties. For the six months ended January 31, 2018, and 2017, we used $0 and $3,483 from financing activities, respectively. For the period ended January 31, 2017, the Company repaid loans to related parties in the amount of $3,483.

 

Limited Operating History; Need for Additional Capital

 

There is no historical financial information about us upon which to base an evaluation of our performance. We are a development stage corporation and have not generated revenues from operations to fully implement our business plan. We cannot guarantee we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources, and competition from larger organizations. We will require equity and/or debt financing to provide for the capital required to implement our plans. We will require additional funds to operate for the next year.

 

We have no assurance that future financing will be available to us on acceptable terms. If financing is not available on satisfactory terms, we may be unable to continue, develop or expand our operations. Equity financing may result in additional dilution to existing shareholders.

 

Liquidity and Capital Resources

 

From May 20, 2014 (inception) through January 31, 2018, we have relied on funds loaned to us by Kratos Healthcare Inc (“Kratos”), a company controlled by an officer and director, to fund our initial working capital requirements. The current amount due is $38,601 in principal, and Kratos has agreed to loan us additional amounts of up to a total of $75,000 (inclusive of cash advances to date).

 

In the event we are not successful in reaching our initial revenue targets, additional funds may be required, and we may not be able to proceed with our business plan for the development and marketing of our core services. Should this occur, we would likely seek additional financing to support the continued operation of our business. We anticipate that depending on market conditions and our plan of operations, we may incur operating losses in the foreseeable future. Therefore, our auditors have raised substantial doubt about our ability to continue as a going concern.

 

As of January 31, 2018, we have no employees. We do not have employment contracts with any of our key employees or controlling shareholders, who are officers and directors of our company.

 

Contractual Obligations

 

As a “smaller reporting company”, we are not required to provide tabular disclosure obligations.

 

 
6
 
Table of Contents

 

Going Concern

 

As of January 31, 2018, our company had a net loss of $19,308 and has earned no revenues. Our company intends to fund operations through equity financing arrangements, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for the year ending July 31, 2018. The ability of our company to emerge from the development stage is dependent upon, among other things, obtaining additional financing to continue operations, and development of our business plan. In response to these problems, management intends to raise additional funds through public or private placement offerings. These factors, among others, raise substantial doubt about our company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

 

Critical Accounting Policies

 

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects of our financial statements is critical to an understanding of our financial statements.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

As a “smaller reporting company”, we are not required to provide the information required by this Item.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

 
7
 
Table of Contents

 

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of January 31, 2018. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms as a result of the following material weaknesses:

 

(1) lack of a functioning audit committee, (2) lack of a majority of outside directors on our board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; (3) inadequate segregation of duties consistent with control objectives; and (4) management is dominated by two individuals without adequate compensating controls.

 

A "material weakness" is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements would not be prevented or detected on a timely basis.

 

We expect to be materially dependent upon a third party to provide us with accounting consulting services for the foreseeable future. Until such time as we have a chief financial officer with the requisite expertise in U.S. GAAP, there are no assurances that the material weaknesses in our disclosure controls and procedures and internal control over financial reporting will not result in errors in our financial statements which could lead to a restatement of those financial statements.

 

Changes in Internal Controls

 

There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the quarter ended January 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 
8
 
Table of Contents

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

From time to time, we may become involved in litigation relating to claims arising out of our operations in the normal course of business. We are not involved in any pending legal proceeding or litigation and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party and which would reasonably be likely to have a material adverse effect on our company. To date, our company has never been involved in litigation, as either a party or a witness, nor has our company been involved in any legal proceedings commenced by any regulatory agency against our company.

 

Item 1A. Risk Factors

 

As a “smaller reporting company”, we are not required to provide the information required by this Item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not Applicable.

 

Item 5. Other Information

 

None.

 

 
9
 
Table of Contents

 

Item 6. Exhibits

 

The following exhibits are included as part of this report:

 

Exhibit Number

Description

(3)

Articles of Incorporation and Bylaws

3.1

Articles of Incorporation (Incorporated by reference to our Registration Statement on Form S-1 filed on September 26, 2014)

3.2

Bylaws (Incorporated by reference to our Registration Statement on Form S-1 filed on September 26, 2014)

(14)

Code of Ethics

14.1

Code of Ethics for Directors, Officers, and Employees (incorporated by reference to exhibit 14.1 in our Registration Statement on Form S-1 filed on September 26, 2014)

14.2

 

Code of Ethics for CEO And Senior Financial Officers (incorporated by reference to exhibit 14.2 in our Registration Statement on Form S-1 filed on September 26, 2014)

(31)

Rule 13a-14 (d)/15d-14d) Certifications

31.1*

Section 302 Certification by the Principal Executive Officer

31.2*

Section 302 Certification by the Principal Financial Officer and Principal Accounting Officer

(32)

Section 1350 Certifications

32.1**

Section 906 Certification by the Principal Executive Officer

32.2**

Section 906 Certification by the Principal Financial Officer and Principal Accounting Officer

101*

Interactive Data File

101.INS

XBRL Instance Document

101.SCH

XBRL Taxonomy Extension Schema Document

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

XBRL Taxonomy Extension Label Linkbase Document

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document

___________ 

*

Filed herewith.

**

Furnished herewith and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

 
10
 
Table of Contents

 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

PANAMERA HEALTHCARE CORPORATION

 

(Registrant)

 

 

Dated: March 19, 2018

 

/s/ Curtis Summers

 

Curtis Summers

 

President, Chief Executive Officer and Director

 

(Principal Executive Officer)

 

 

Dated: March 19, 2018

 

/s/ Douglas G. Baker

 

Douglas G. Baker

 

Secretary, Chief Financial Officer, Treasurer and Director

 

(Principal Financial Officer and Principal Accounting Officer)

 

 

 11